Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the appointment of Andrew Eisen, M.D., Ph.D. as VP, Clinical Development. Dr. Eisen is a translational medicine and clinical development specialist with over 20 years of experience in the biotech and pharma sectors.
For Jim Allison, cancer has always been at the back of his mind. He’d lost many family members to the disease, including his mother when he was young, and is himself a cancer survivor.
The University of Maryland (UM) BioPark and Wexford Science & Technology, LLC, today announced Illumina, Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems, as the newest tenant in the UM BioPark’s 801 W. Baltimore St. building. The building is owned by Ventas, Inc., a life sciences real estate investment trust (REIT) and is part of Wexford’s Knowledge Community development at the UM BioPark.
Watch this video on the Dutch biopharmaceutical industry in the Netherlands and get inspired by the Dutch. The perfect location to build your biopharmaceutical business. We open our doors for you!
Sea levels are rising, and that is sending more ocean water into streets, sewers and homes. For people who live and work in coastal communities, that means more otherwise-sunny days disrupted by flooding.
A tech company in Charlottesville is being recognized for its groundbreaking data that could help treat chronic illnesses.
New research done by AMPEL BioSolutions shows that a blood sample, when paired with its computer coding, can detect disease activity in patients who have lupus or other autoimmune diseases.
Maryland biotech Altimmune Inc. has reached an agreement to acquire California drug developer Spitfire Pharma Inc. in a move that sent the local company’s stock skyrocketing Tuesday.
Each of the seven startups received $150,000. To date in fiscal year 2019, $4.22 million in investments have been made through the Maryland Innovation Initiative program.
In honor of the new JLABS @ Washington, DC – a 32,000 square foot facility located on the new Children’s National Research and Innovation Campus from Johnson & Johnson Innovation, LLC in partnership with Children’s National Health System[1] (“Children’s National”) – Johnson & Johnson Innovation – JLABS announces the JLABS @ Washington, DC Children’s QuickFire Challenge.
Visionaries within the fields of pediatric oncology, pediatric surgery and influenza are invited to submit innovative ideas for a total of up to $150,000 in total grant funding; one year of residency at JLABS @ Washington, DC with the use of a bench, workstation, and access to the JLABS @ Washington, DC community; and mentorship from experts at the Johnson & Johnson Family of Companies.
